Scott Gottlieb, MD, President Donald J. Trump’s nominee for FDA Commissioner, testified before the Senate Committee on Health, Education, Labor & Pensions at his confirmation hearing today that he would be an impartial and passionate advocate for public health. In his opening statement, he said that he would seek the most “bang for our regulatory buck” while being cognizant of risks and being sure to not add to consumer costs without improving consumer safety. He stressed his belief in the “gold standard of safety and efficacy” at the agency and said he hopes to expand approvals of generic drugs to lower US drug prices. “I think there are ways to modernize clinical studies without sacrificing the gold standard,” Gottlieb said.
A fellow at the American Enterprise Institute and former deputy commissioner of medical and scientific affairs at the FDA, Gottlieb has held senior posts at the CMS under former President George W. Bush. He has expressed opposition to many FDA regulations, including FDA efforts to regulate diagnostics that could impact innovation. During the 2016 Patient-Centered Oncology Care meeting hosted by The American Journal of Managed Care®, Gottlieb discussed possibilities for repealing and replacing the Affordable Care Act, including fewer restrictions on what he called “very tight actuarial banding” that “doesn’t allow for experimentation in benefit design.”
Gottlieb has been involved in venture capital and investment banking firms that invest in biomedical startups, and has his own consulting firm. He has served on numerous boards of pharmaceutical companies, which has helped him gain the support of pharmaceutical industry leaders but simultaneously raised concerns among critics worried about conflicts of interests. Gottlieb has vowed to recuse himself from issues related to the nearly 2 dozen companies he has ties to, and said he would divest himself of medical company stocks and would resign from his other positions.
As a Forbes contributor, Gottlieb has written about streamlining the generic drug approval process and has advocated the end of drug rebates as a way to lower drug prices. “If insurers could demand up-front discounts, rather than back-ended rebates, and drug makers were free to offer them, then more of the markdown would come in the form of lower opening prices,” he stated in a September 2016 column.
In response to questioning from Senator Patty Murray of Washington about whether the FDA under Gottlieb would exercise independent, science-based decision making, Gottlieb said that would be his goal because people’s lives were at stake. “I’ll be guided by the science and by the expertise of the career staff,” he said. Murray noted Gottlieb’s financial ties to companies that she said have 60 drugs that could come before the FDA. When asked by Senators if he would resist FDA staffing cuts proposed by President Trump, Gottlieb said, “I’m going to be committed to advocate for a strong FDA, for strong resources at the FDA,” and said he hadn’t been shy about expressing his views to bosses.
Gottlieb said his first priority as FDA Commissioner would be findings ways to fight the opioid crisis, which required dramatic action. He called for reevaluating the way FDA currently develops alternatives to opioid drugs, and how the agency views medical devices and medically assisted therapy for people struggling with addiction.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.